Significance of Findings in RESPONSE Trial in Polycythemia Vera

In an interview with Targeted Oncology, Craig Sauter, MD, discusses available treatments for patients with central nervous system lymphoma and research that will provide more developments moving forward in this space.

In an interview with Targeted Oncology, Raajit K. Rampal, MD, PhD, discussed the currently approved JAK inhibitors used to treat patients with myelofibrosis, and exciting movements in the field.

In an interview, Krisda Chaiyachati, MD, MPH, discussed some of the social determinants of health for patients with cancer and some of the challenges patients undergoing treatment face, including transportation insecurity.

In an interview with Targeted Oncology, Jennifer Y. Wo, MD, highlighted emerging discussions in the metastatic colorectal cancer space, where targeted therapies play a role, and what the next steps for research include.

In an interview, Edwin Choy, MD, discussed the treatment landscape of GIST and recent changes to NCCN guidelines.

In an interview with Targeted Oncology, Aaron T. Gerds, MD, MS, provided an in-depth discussion on the complete response letter issued to ruxolitinib extended-release, and why continued evaluation of the agent could be beneficial for patients with MPNs.